Corbus Pharmaceuticals Holdings, Inc.

As of March 8, 2022, Corbus Pharmaceuticals is considered overvalued due to its financial metrics, including a Price to Book Value of 0.89 and an EV to EBITDA of 0.32, while its stock has underperformed significantly with a year-to-date return of -33.14%.

As of April 22, 2025, the market trend is mildly bearish due to daily moving averages and monthly MACD signals, despite some mildly bullish indicators on the weekly charts, suggesting a cautious approach is advisable.

As of March 2022, the management team of Corbus Pharmaceuticals Holdings, Inc. includes Mr. Alan Holmer (Independent Chairman), Mr. Yuval Cohen (CEO), and several Independent Directors: Mr. Avery Catlin, Ms. Rachelle Jacques, Dr. John Jenkins, and Dr. Peter Salzmann. They oversee the company's strategic direction and operations.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for rare inflammatory and fibrotic diseases. It has a market cap of $101.32 million and reported a net profit loss of $17 million as of March 2025.

As of Jun 18, Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of 101.32 million, with net sales of 0.00 million and a net profit of -50.29 million over the last four quarters. The company's shareholder's funds are 142.43 million, and total assets amount to 155.88 million.